Patents Assigned to Neurodon Corporation
  • Quinolines that modulate SERCA and their use for treating disease
    Patent number: 11992487
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Grant
    Filed: August 2, 2023
    Date of Patent: May 28, 2024
    Assignee: Neurodon Corporation
    Inventor: Russell Dahl
  • Quinolines that modulate SERCA and their use for treating disease
    Patent number: 11890279
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Grant
    Filed: May 19, 2023
    Date of Patent: February 6, 2024
    Assignee: Neurodon Corporation
    Inventor: Russell Dahl
  • Quinolines that modulate SERCA and their use for treating disease
    Patent number: 11827626
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: November 28, 2023
    Assignee: NEURODON CORPORATION
    Inventor: Russell Dahl
  • Quinolines that modulate SERCA and their use for treating disease
    Patent number: 11730729
    Abstract: Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: August 22, 2023
    Assignee: Neurodon Corporation
    Inventor: Russell Dahl